Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + famitinib plus chemotherapy as neoadjuvant therapy in advanced ovarian cancer
ChiCTR2600117773Phase 2Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cadonilimab and famitinib in ovarian cancer (2 arms), sponsored by Xinhua Hospital. Primary endpoints: R0 surgical resection rate and Safety (treatment-related adverse events). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
cadonilimabfamitinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2600117773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117773.